This trial will comprehensively characterize circadian system dysfunction in BED, and evaluate it as a potential therapeutic target.
2 Primary · 7 Secondary · Reporting Duration: Phase 2 baseline (visit 0) to endpoint, on average one month.
80 Total Participants · 0 Treatment Group
Primary Treatment: Treatment · Has Placebo Group · Phase 1 & 2
Participation is compensated
You will be compensated for participating in this trial.
Age 18 - 50 · All Participants · 10 Total Inclusion Criteria
Mark “Yes” if the following statements are true for you: